Delcath’s Targeted Liver Cancer Therapy Gains Spotlight at Key Medical Meeting

QUEENSBURY, N.Y. – April 01, 2026 – Delcath Systems, an interventional oncology firm making significant inroads in the treatment of liver cancers, is poised for a major showcase at the upcoming Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting. The event, held in Toronto from April 11–15, will feature the company's innovative Hepatic Delivery System in three separate presentations by leading physicians, signaling growing clinical adoption and reinforcing the technology's role in a rapidly evolving field.

For investors and the medical community, the presentations offer a critical glimpse into the real-world performance of the HEPZATO KIT, a drug-device combination that has become a beacon of hope for patients with a particularly challenging form of cancer. This moment at SIR 2026 represents a confluence of clinical validation, technological advancement, and burgeoning commercial success for the Queensbury-based company.

A New Dawn for a Difficult Disease

Metastatic uveal melanoma (mUM) is a rare but aggressive cancer of the eye that frequently metastasizes to the liver. Once the disease spreads, treatment options are notoriously limited, and the prognosis is often poor. Delcath Systems has directly targeted this unmet need with its proprietary technology, a procedure known as percutaneous hepatic perfusion (PHP).

The HEPZATO KIT facilitates this procedure by temporarily isolating the liver's circulatory system from the rest of the body. This allows for the delivery of a high dose of the chemotherapy drug melphalan directly to the liver, where the tumors reside. Simultaneously, the system filters the blood leaving the liver before it is returned to the body, significantly reducing the systemic toxicity that often accompanies traditional chemotherapy. This loco-regional approach allows for a powerful, targeted attack on the cancer while protecting the patient from debilitating side effects.

The FDA granted approval for the HEPZATO KIT to treat adult patients with mUM with unresectable hepatic metastases, based on compelling results from the pivotal Phase 3 FOCUS study. Further validation came from the recent publication of the CHOPIN trial in The Lancet Oncology, which demonstrated significant clinical benefit when PHP is sequenced with modern checkpoint inhibitor immunotherapies. The study highlighted a remarkable improvement in one-year progression-free survival, cementing the therapy's place in the treatment arsenal.

The upcoming SIR meeting will build on this foundation with presentations detailing firsthand clinical experience. Dr. David Eschelman of Thomas Jefferson University and Dr. Mustafa Ege Seker from the University of Wisconsin are scheduled to present their initial commercial and preliminary clinical experiences, respectively. These sessions are expected to provide invaluable real-world data on patient outcomes and practical application, moving the conversation from the controlled environment of a clinical trial to the complexities of daily medical practice.

Redefining Treatment in Interventional Oncology

Delcath's technology is not just an incremental improvement; it represents a paradigm shift within the broader field of interventional oncology. This medical subspecialty has been steadily moving away from one-size-fits-all systemic treatments and towards minimally invasive, highly targeted therapies that attack cancer at its source. The global interventional oncology market, valued at nearly $3 billion in 2025, is projected to more than double by 2035, driven by this demand for precision and efficacy.

Within this landscape, treatments for liver malignancies like Transarterial Chemoembolization (TACE) and Transarterial Radioembolization (TARE) have become standard. However, Delcath's PHP offers a distinct and powerful alternative. By saturating the entire liver organ with a potent chemotherapeutic agent, it provides a comprehensive treatment that other embolization techniques may not achieve, particularly for diffuse disease.

The SIR Annual Meeting is the premier venue for showcasing such advancements. The inclusion of a presentation on HEPZATO's user experience at the SIR Innovation Hub, to be led by Dr. Eric Wehrenberg-Klee of Massachusetts General Hospital and Harvard Medical School, is particularly noteworthy. This session will delve into the practicalities of integrating PHP into a hospital's workflow and its use in combination with systemic immunotherapies, reflecting the cutting-edge of cancer care. For interventional radiologists in attendance, hearing from a peer at a top-tier institution provides the kind of validation that drives practice change and wider adoption.

From Clinical Promise to Commercial Powerhouse

The growing clinical acceptance of HEPZATO is mirrored by Delcath's impressive financial and commercial trajectory. The company reported a record-breaking $85.2 million in revenue for 2025, a more than 40% increase over the previous year. This surge was overwhelmingly driven by sales of the HEPZATO KIT in the United States, which saw procedure volumes grow by an astonishing 140%.

This rapid commercial ramp-up enabled the company to achieve full-year profitability in 2025, posting a net income of $2.7 million—a dramatic turnaround from a $26.4 million loss in 2024. With a healthy cash reserve of $91 million and no debt, Delcath is well-capitalized to fuel its expansion.

The company's guidance for 2026 projects continued momentum, with total revenue expected to surpass $100 million. A key pillar of this growth strategy is the expansion of its treatment center network. Having ended 2025 with 28 active sites, Delcath aims to have HEPZATO available at 40 leading U.S. cancer centers by the end of 2026. The presentations at SIR 2026 are a vital component of this commercial strategy, serving as a powerful marketing and educational tool to attract and train new centers. As one analyst noted, "Physicians want to see the data, but they also want to hear from their colleagues who are using the technology. Events like SIR are where that happens."

Beyond the Horizon: Expanding the Battlefield

While metastatic uveal melanoma provided the initial beachhead for FDA approval, Delcath has its sights set on a much larger territory. The company is significantly increasing its investment in research and development, with a projected 90% rise in R&D spending for 2026. This investment is aimed squarely at expanding the clinical applications of its Hepatic Delivery System.

The company has already announced plans to initiate new Phase 2 clinical trials to evaluate HEPZATO for the treatment of liver metastases originating from other common and deadly cancers, including metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC). Success in these areas would exponentially increase the therapy's addressable market and clinical impact.

This strategy has a proven precedent. In Europe, the device-only version of the system, marketed as CHEMOSAT, is already approved and used to treat a wide range of primary and metastatic liver cancers. This extensive European experience provides a valuable roadmap and a wealth of data that can inform and potentially accelerate Delcath's regulatory and clinical pathway in the United States. As the company continues to execute its strategy, its technology could evolve from a niche treatment for a rare cancer into a foundational therapy for a broad spectrum of patients suffering from liver-dominant malignancies.